A Prospective Randomized Multicenter Study of Flecainide Acetate Oral Inhalation Solution in Single and Repeat Dose Regimens for Acute Conversion to Sinus Rhythm in Subjects With Recent Onset of Symptomatic Paroxysmal Atrial Fibrillation
Phase of Trial: Phase II
Latest Information Update: 26 Nov 2019
Price : $35 *
At a glance
- Drugs Flecainide (Primary)
- Indications Paroxysmal atrial fibrillation
- Focus Therapeutic Use
- Acronyms INSTANT
- Sponsors InCarda Therapeutics
- 24 Sep 2019 Planned number of patients changed from 100 to 150.
- 05 Aug 2019 Planned number of patients changed from 140 to 100.
- 05 Aug 2019 Planned End Date changed from 1 Apr 2019 to 1 May 2021.